48 results
Page 2 of 3
8-K
EX-10.1
uw0f38vmmnw
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-99.1
tjlq zqojbasvj
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
424B5
q2dim1b
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
sba 101jl4
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
w3dlq xez5r6
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
q7525u0 q7f077t3on7
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.1
bxhi0wt3o0 lk3
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
EX-99.2
o5omnq98 ti
23 Nov 20
Consolidated Financial Statements
12:00am
424B3
me3rg gbb
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
ttw08lhvz
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
s1iwmga
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-2.1
1q2 mesbxxds2k8pt0r
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
425
yauw9v jc7
22 Jun 20
Business combination disclosure
5:30pm
8-K
EX-99.4
5hb1i 68y
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.2
1b80cbsz7y
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm